Switch to:
Also traded in: Germany, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
HEB's Cash-to-Debt is ranked higher than
96% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. HEB: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
HEB' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.35  Med: 9455 Max: No Debt
Current: No Debt
Equity-to-Asset 0.77
HEB's Equity-to-Asset is ranked higher than
66% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. HEB: 0.77 )
Ranked among companies with meaningful Equity-to-Asset only.
HEB' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.53  Med: 0.86 Max: 0.98
Current: 0.77
0.53
0.98
Piotroski F-Score: 3
Altman Z-Score: -18.81
Beneish M-Score: -2.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -12196.12
HEB's Operating Margin % is ranked lower than
93% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. HEB: -12196.12 )
Ranked among companies with meaningful Operating Margin % only.
HEB' s Operating Margin % Range Over the Past 10 Years
Min: -12518.8  Med: -9622.11 Max: -1821.44
Current: -12196.12
-12518.8
-1821.44
Net Margin % -9190.29
HEB's Net Margin % is ranked lower than
92% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. HEB: -9190.29 )
Ranked among companies with meaningful Net Margin % only.
HEB' s Net Margin % Range Over the Past 10 Years
Min: -11451.13  Med: -7307.95 Max: -1712.84
Current: -9190.29
-11451.13
-1712.84
ROE % -49.27
HEB's ROE % is ranked lower than
56% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. HEB: -49.27 )
Ranked among companies with meaningful ROE % only.
HEB' s ROE % Range Over the Past 10 Years
Min: -89.44  Med: -54.06 Max: -20.44
Current: -49.27
-89.44
-20.44
ROA % -41.41
HEB's ROA % is ranked lower than
57% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. HEB: -41.41 )
Ranked among companies with meaningful ROA % only.
HEB' s ROA % Range Over the Past 10 Years
Min: -69.18  Med: -46.58 Max: -18.36
Current: -41.41
-69.18
-18.36
ROC (Joel Greenblatt) % -88.45
HEB's ROC (Joel Greenblatt) % is ranked higher than
66% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. HEB: -88.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HEB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -386.32  Med: -229.74 Max: -88.45
Current: -88.45
-386.32
-88.45
3-Year Revenue Growth Rate -27.00
HEB's 3-Year Revenue Growth Rate is ranked lower than
77% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. HEB: -27.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HEB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -59.5  Med: -10.9 Max: 59.4
Current: -27
-59.5
59.4
3-Year EBITDA Growth Rate -20.50
HEB's 3-Year EBITDA Growth Rate is ranked lower than
74% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. HEB: -20.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
HEB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -29.1  Med: -6.3 Max: 16.5
Current: -20.5
-29.1
16.5
3-Year EPS without NRI Growth Rate -20.60
HEB's 3-Year EPS without NRI Growth Rate is ranked lower than
70% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. HEB: -20.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
HEB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -39.1  Med: -6.1 Max: 19.7
Current: -20.6
-39.1
19.7
GuruFocus has detected 3 Warning Signs with Hemispherx Biopharma Inc $HEB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HEB's 10-Y Financials

Financials (Next Earnings Date: 2017-03-29)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

HEB Guru Trades in

HEB Guru Trades in

Q3 2016

HEB Guru Trades in Q3 2016

Jim Simons 158,152 sh (New)
» More
Q4 2016

HEB Guru Trades in Q4 2016

Jim Simons 139,952 sh (-11.51%)
» More
» Details

Insider Trades

Latest Guru Trades with HEB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OTCPK:BLUSF, NAS:JAGX, OTCPK:ENZN, NAS:DPRX, OTCBB:DDRT, NAS:SNGX, NAS:ORPN, NAS:GNVC, OTCPK:IPATF, OTCPK:ATTBF, NAS:MBRX, OTCPK:CRRTF, OTCPK:PPGNY, OTCPK:CLCS, OTCPK:ZIVO, OTCPK:LBLTF, OTCPK:ETBI, OTCPK:BCTXF, OTCPK:QUEZF, NAS:OCRX » details
Traded in other countries:HXB1.Germany, HEB.Switzerland,
Hemispherx Biopharma Inc is a specialty pharmaceutical company. It is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.

Hemispherx Biopharma Inc is a Delaware Corporation founded in the early 1970s. The Company is a specialty pharmaceutical company. It is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Since its inception, it has established a foundation of laboratory, pre-clinical and clinical data with respect to the development of natural interferon and nucleic acids to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain chronic diseases. The Company owns and operates a 43,000 sq. ft. manufacturing facility in New Brunswick, NJ that produces Alferon and Ampligen. The Company operates in one segment, which performs research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's primary pharmaceutical product platform consists of its experimental compound, Ampligen, its FDA approved natural interferon product, Alferon N Injection and, its experimental liquid natural interferon for oral administration, Alferon LDO (Low Dose Oral). As of December 31, 2013, the Company had 25 patents. Its potential competitors are among the pharmaceutical companies in the world, are well known to the public and the medical community, and have substantially greater financial resources, product development, and manufacturing and marketing capabilities. The Company is subject to various federal, state and local laws, regulations and recommendations relating to such matters as safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use of and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its research work.

Ratios

vs
industry
vs
history
PB Ratio 0.77
HEB's PB Ratio is ranked higher than
93% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. HEB: 0.77 )
Ranked among companies with meaningful PB Ratio only.
HEB' s PB Ratio Range Over the Past 10 Years
Min: 0.6  Med: 1.83 Max: 13.74
Current: 0.77
0.6
13.74
PS Ratio 102.00
HEB's PS Ratio is ranked lower than
83% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. HEB: 102.00 )
Ranked among companies with meaningful PS Ratio only.
HEB' s PS Ratio Range Over the Past 10 Years
Min: 44.49  Med: 233.93 Max: 2630.77
Current: 102
44.49
2630.77
Current Ratio 3.84
HEB's Current Ratio is ranked lower than
52% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. HEB: 3.84 )
Ranked among companies with meaningful Current Ratio only.
HEB' s Current Ratio Range Over the Past 10 Years
Min: 1.36  Med: 5.15 Max: 44.82
Current: 3.84
1.36
44.82
Quick Ratio 3.84
HEB's Quick Ratio is ranked higher than
50% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. HEB: 3.84 )
Ranked among companies with meaningful Quick Ratio only.
HEB' s Quick Ratio Range Over the Past 10 Years
Min: 1.36  Med: 4.92 Max: 44.19
Current: 3.84
1.36
44.19
Days Inventory 385.33
HEB's Days Inventory is ranked lower than
90% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. HEB: 385.33 )
Ranked among companies with meaningful Days Inventory only.
HEB' s Days Inventory Range Over the Past 10 Years
Min: 67  Med: 270 Max: 389.91
Current: 385.33
67
389.91
Days Payable 308.54
HEB's Days Payable is ranked higher than
87% of the 341 Companies
in the Global Biotechnology industry.

( Industry Median: 59.13 vs. HEB: 308.54 )
Ranked among companies with meaningful Days Payable only.
HEB' s Days Payable Range Over the Past 10 Years
Min: 277.06  Med: 417.31 Max: 808.75
Current: 308.54
277.06
808.75

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.10
HEB's 3-Year Average Share Buyback Ratio is ranked lower than
59% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. HEB: -14.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HEB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.7  Med: -14.1 Max: -4.9
Current: -14.1
-25.7
-4.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.92
HEB's Price-to-Net-Cash is ranked higher than
62% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. HEB: 3.92 )
Ranked among companies with meaningful Price-to-Net-Cash only.
HEB' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.06  Med: 8.52 Max: 191.38
Current: 3.92
1.06
191.38
Price-to-Net-Current-Asset-Value 2.83
HEB's Price-to-Net-Current-Asset-Value is ranked higher than
72% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. HEB: 2.83 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
HEB' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.01  Med: 7.59 Max: 154.17
Current: 2.83
1.01
154.17
Price-to-Tangible-Book 0.78
HEB's Price-to-Tangible-Book is ranked higher than
94% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. HEB: 0.78 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HEB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.71  Med: 5.55 Max: 154.17
Current: 0.78
0.71
154.17
Price-to-Median-PS-Value 0.44
HEB's Price-to-Median-PS-Value is ranked higher than
82% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. HEB: 0.44 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HEB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.99 Max: 11.61
Current: 0.44
0.15
11.61
Earnings Yield (Greenblatt) % -219.61
HEB's Earnings Yield (Greenblatt) % is ranked lower than
95% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. HEB: -219.61 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HEB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -232.66  Med: 396.7 Max: 2162.6
Current: -219.61
-232.66
2162.6

More Statistics

Revenue (TTM) (Mil) $0.10
EPS (TTM) $ -0.47
Beta-0.36
Short Percentage of Float2.25%
52-Week Range $0.39 - 2.64
Shares Outstanding (Mil)24.11

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) 0.04 0.24 0.48
EPS without NRI ($) 0.04 0.24 0.48
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for HEB

Headlines

Articles On GuruFocus.com
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-K/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CEO Sells Highlight: Hemispherx Biopharma Inc, ADESA Inc, Entergy Corp, and Danaher Corp. Aug 15 2010 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Aug 06 2010 
Hemispherx Biopharma Inc (HEB) CEO William A Carter buys 500,000 Shares Jul 01 2010 
Weekly CFO Buys Highlight: Wireless Telecom Group, ValueVision Media, American River Bankshares, Hem Dec 12 2009 
Hemispherx Biopharma Inc (HEB) CFO Charles Thomas Iii Bernhardt buys 2,000 Shares Dec 08 2009 

More From Other Websites
Hemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017 Mar 06 2017
Why President Trump Wants To Transform The FDA – And What It Could Mean For Biotech Stocks Feb 23 2017
$1M deal: Hemispherx plans to sell stock, warrants Feb 03 2017
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Feb 03 2017
Hemispherx Biopharma, Inc. Announces $1 Million Registered Direct Offering Feb 02 2017
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Regulation FD Disclosure Feb 01 2017
Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to... Jan 26 2017
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jan 17 2017
Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to... Jan 11 2017
ETFs with exposure to Hemispherx Biopharma, Inc. : January 3, 2017 Jan 03 2017
HEMISPHERX BIOPHARMA INC Financials Dec 31 2016
ETFs with exposure to Hemispherx Biopharma, Inc. : December 19, 2016 Dec 19 2016
ETFs with exposure to Hemispherx Biopharma, Inc. : December 8, 2016 Dec 08 2016
Crystal Research Associates, LLC Issues Executive Informational Overview on Hemispherx Biopharma,... Dec 01 2016
ETFs with exposure to Hemispherx Biopharma, Inc. : November 23, 2016 Nov 23 2016
Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016 Nov 21 2016
Hemispherx 3Q Loss $2.9M or 13 Cents a Share (HEB) Nov 16 2016
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 15 2016
Hemispherx Biopharma Announces Financial Results in its Quarterly Report for the Nine Months Ended... Nov 14 2016
Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on November 15,... Nov 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)